Tazemetostat in combination with topotecan and pembrolizumab in patients with recurrent small cell lung cancer

被引：0
|
作者：
Desai, Parth Anil
Takahashi, Nobuyuki
Lissa, Delphine
Nichols, Samantha
Sciuto, Linda
Abel, Melissa Lauren
Schroeder, Brett
Schultz, Christopher
Steinberg, Seth M.
Pinkiert, Danielle
Vilimas, Rasa J.
Thomas, Anish
机构：
[1] Temple Univ, Fox Chase Canc Ctr, Philadelphia, PA USA
[2] Natl Canc Ctr Hosp East, Shinjuku Ku, Kashiwa, Chiba, Japan
[3] AstraZeneca, Cambridge, England
[4] NCI, Dev Therapeut Branch, Ctr Canc Res, Bethesda, MD USA
[5] NIH, Bethesda, MD USA
[6] NCI, Bethesda, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8130
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Topotecan in the treatment of relapsed small cell lung cancer
    Quoix, Elisabeth
    ONCOTARGETS AND THERAPY, 2008, 1 : 79 - 86
  • [22] Phase I Study of Topotecan and Cisplatin in Patients with Small Cell Lung Cancer
    Ichinose, Yukito
    Seto, Takashi
    Nishiwaki, Yutaka
    Kiura, Katsuyuki
    Sakai, Hiroshi
    Yokoyama, Akira
    Segawa, Yoshihiko
    Ando, Masahiro
    Watanabe, Koshiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (02) : 197 - 203
  • [23] Phase II trial of weekly topotecan with docetaxel in recurrent small cell lung cancer (Aultman Lung 01)
    Khan, R. A.
    Hahn, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer
    Garst, Jennifer
    Buller, Richard
    Lane, Stephen
    Crawford, Jeffrey
    CLINICAL LUNG CANCER, 2005, 7 (03) : 190 - 196
  • [25] A phase II trial of combination chemotherapy with topotecan and amrubicin in small cell lung cancer (SCLC).
    Nogami, N.
    Kiura, K.
    Takigawa, N.
    Harita, S.
    Chikamori, K.
    Shibayama, T.
    Tabata, M.
    Hotta, K.
    Shinkai, T.
    Tanimoto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] Pembrolizumab in Combination with Chemotherapy in Patients with ERBB2-Mutated Non-Small Cell Lung Cancer
    Fawzi Abu Rous
    Radhika Gutta
    Pin Li
    Balazs Halmos
    Shirish Gadgeel
    Targeted Oncology, 2022, 17 : 187 - 192
  • [27] Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer
    Zarogoulidis, K.
    Mylonaki, E.
    Kakavelas, P.
    Zarogoulidis, P.
    Tsiouda, Th.
    Rapti, E.
    Lithoxopoulou, H.
    Zarogoulidou, V.
    Kontakiotis, Th.
    LUNG CANCER, 2009, 66 (02) : 226 - 230
  • [28] Pembrolizumab in Combination with Chemotherapy in Patients with ERBB2-Mutated Non-Small Cell Lung Cancer
    Abu Rous, Fawzi
    Gutta, Radhika
    Li, Pin
    Halmos, Balazs
    Gadgeel, Shirish
    TARGETED ONCOLOGY, 2022, 17 (02) : 187 - 192
  • [29] Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer
    Matthew A Beldner
    Carol A Sherman
    Mark R Green
    Elizabeth Garrett-Mayer
    Uzair Chaudhary
    Mario L Meyer
    Andrew S Kraft
    Alberto J Montero
    BMC Cancer, 7
  • [30] Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer
    Beldner, Matthew A.
    Sherman, Carol A.
    Green, Mark R.
    Garrett-Mayer, Elizabeth
    Chaudhary, Uzair
    Meyer, Mario L.
    Kraft, Andrew S.
    Montero, Alberto J.
    BMC CANCER, 2007, 7 (1)
12345